2 reports of this reaction
4.3% of all LIDOCAINE HCI reports
#2 most reported adverse reaction
ASTHENIA is the #2 most commonly reported adverse reaction for LIDOCAINE HCI, manufactured by Aurobindo Pharma Limited. There are 2 FDA adverse event reports linking LIDOCAINE HCI to ASTHENIA. This represents approximately 4.3% of all 47 adverse event reports for this drug.
Patients taking LIDOCAINE HCI who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is moderately reported among LIDOCAINE HCI users, representing a notable but not dominant share of adverse events.
In addition to asthenia, the following adverse reactions have been reported for LIDOCAINE HCI:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 2 FDA reports for LIDOCAINE HCI. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 4.3% of all adverse event reports for LIDOCAINE HCI, making it one of the most commonly reported side effect.
If you experience asthenia while taking LIDOCAINE HCI, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.